Click for best price
Metastatic Ovarian Cancer Drug Market Size, Share 2022
This report contains market size and forecasts of Metastatic Ovarian Cancer Drug in global, including the following market information:
Global Metastatic Ovarian Cancer Drug Market Revenue, 2017-2022, 2023-2028, ($ millions)
Global Metastatic Ovarian Cancer Drug Market Sales, 2017-2022, 2023-2028, (K Pcs)
Global top five Metastatic Ovarian Cancer Drug companies in 2021 (%)
The global Metastatic Ovarian Cancer Drug market was valued at million in 2021 and is projected to reach US$ million by 2028, at a CAGR of % during the forecast period.
The U.S. Market is Estimated at $ Million in 2021, While China is Forecast to Reach $ Million by 2028.
E-7449 Segment to Reach $ Million by 2028, with a % CAGR in next six years.
The global key manufacturers of Metastatic Ovarian Cancer Drug include Adgero Biopharmaceuticals Inc, Cellceutix Corporation, Eisai Co., Ltd., F. Hoffmann-La Roche Ltd., Immune Design Corp., Millennium Pharmaceuticals Inc, MolMed S.p.A., Natco Pharma Limited and Northwest Biotherapeutics, Inc., etc. In 2021, the global top five players have a share approximately % in terms of revenue.
We surveyed the Metastatic Ovarian Cancer Drug manufacturers, suppliers, distributors and industry experts on this industry, involving the sales, revenue, demand, price change, product type, recent development and plan, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global Metastatic Ovarian Cancer Drug Market, by Type, 2017-2022, 2023-2028 ($ Millions) & (K Pcs)
Global Metastatic Ovarian Cancer Drug Market Segment Percentages, by Type, 2021 (%)
E-7449
Crizotinib
CMB-305
G-305
LV-305
Others
Global Metastatic Ovarian Cancer Drug Market, by Application, 2017-2022, 2023-2028 ($ Millions) & (K Pcs)
Global Metastatic Ovarian Cancer Drug Market Segment Percentages, by Application, 2021 (%)
Clinic
Hospital
Others
Global Metastatic Ovarian Cancer Drug Market, By Region and Country, 2017-2022, 2023-2028 ($ Millions) & (K Pcs)
Global Metastatic Ovarian Cancer Drug Market Segment Percentages, By Region and Country, 2021 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Competitor Analysis
The report also provides analysis of leading market participants including:
Key companies Metastatic Ovarian Cancer Drug revenues in global market, 2017-2022 (Estimated), ($ millions)
Key companies Metastatic Ovarian Cancer Drug revenues share in global market, 2021 (%)
Key companies Metastatic Ovarian Cancer Drug sales in global market, 2017-2022 (Estimated), (K Pcs)
Key companies Metastatic Ovarian Cancer Drug sales share in global market, 2021 (%)
Further, the report presents profiles of competitors in the market, key players include:
Adgero Biopharmaceuticals Inc
Cellceutix Corporation
Eisai Co., Ltd.
F. Hoffmann-La Roche Ltd.
Immune Design Corp.
Millennium Pharmaceuticals Inc
MolMed S.p.A.
Natco Pharma Limited
Northwest Biotherapeutics, Inc.
Pfizer Inc.
Richter Gedeon Nyrt.
Sumitomo Dainippon Pharma Co., Ltd.
VG Life Sciences, Inc.
| Report Attributes |
Report Details |
| Report Title |
Metastatic Ovarian Cancer Drug Market, Global Outlook and Forecast 2022-2028 |
| Historical Year |
2018 to 2022 (Data from 2010 can be provided as per availability) |
| Base Year |
2021 |
| Forecast Year |
2029 |
| Number of Pages |
78 Pages |
| Customization Available |
Yes, the report can be customized as per your need. |
TABLE OF CONTENTS
1 Introduction to Research & Analysis Reports
1.1 Metastatic Ovarian Cancer Drug Market Definition
1.2 Market Segments
1.2.1 Market by Type
1.2.2 Market by Application
1.3 Global Metastatic Ovarian Cancer Drug Market Overview
1.4 Features & Benefits of This Report
1.5 Methodology & Sources of Information
1.5.1 Research Methodology
1.5.2 Research Process
1.5.3 Base Year
1.5.4 Report Assumptions & Caveats
2 Global Metastatic Ovarian Cancer Drug Overall Market Size
2.1 Global Metastatic Ovarian Cancer Drug Market Size: 2021 VS 2028
2.2 Global Metastatic Ovarian Cancer Drug Revenue, Prospects & Forecasts: 2017-2028
2.3 Global Metastatic Ovarian Cancer Drug Sales: 2017-2028
3 Company Landscape
3.1 Top Metastatic Ovarian Cancer Drug Players in Global Market
3.2 Top Global Metastatic Ovarian Cancer Drug Companies Ranked by Revenue
3.3 Global Metastatic Ovarian Cancer Drug Revenue by Companies
3.4 Global Metastatic Ovarian Cancer Drug Sales by Companies
3.5 Global Metastatic Ovarian Cancer Drug Price by Manufacturer (2017-2022)
3.6 Top 3 and Top 5 Metastatic Ovarian Cancer Drug Companies in Global Market, by Revenue in 2021
3.7 Global Manufacturers Metastatic Ovarian Cancer Drug Product Type
3.8 Tier 1, Tier 2 and Tier 3 Metastatic Ovarian Cancer Drug Players in Global Market
3.8.1 List of Global Tier 1 Metastatic Ovarian Cancer Drug Companies
3.8.2 List of Global Tier 2 and Tier 3 Metastatic Ovarian Cancer Drug Companies
4 Sights by Product
4.1 Overview
4.1.1 By Type - Global Metastatic Ovarian Cancer Drug Market Size Markets, 2021 & 2028
4.1.2 E-7449
4.1.3 Crizotinib
4.1.4 CMB-305
4.1.5 G-305
4.1.6 LV-305
4.1.7 Others
4.2 By Type - Global Metastatic Ovarian Cancer Drug Revenue & Forecasts
4.2.1 By Type - Global Metastatic Ovarian Cancer Drug Revenue, 2017-2022
4.2.2 By Type - Global Metastatic Ovarian Cancer Drug Revenue, 2023-2028
4.2.3 By Type - Global Metastatic Ovarian Cancer Drug Revenue Market Share, 2017-2028
4.3 By Type - Global Metastatic Ovarian Cancer Drug Sales & Forecasts
4.3.1 By Type - Global Metastatic Ovarian Cancer Drug Sales, 2017-2022
4.3.2 By Type - Global Metastatic Ovarian Cancer Drug Sales, 2023-2028
4.3.3 By Type - Global Metastatic Ovarian Cancer Drug Sales Market Share, 2017-2028
4.4 By Type - Global Metastatic Ovarian Cancer Drug Price (Manufacturers Selling Prices), 2017-2028
5 Sights By Application
5.1 Overview
5.1.1 By Application - Global Metastatic Ovarian Cancer Drug Market Size, 2021 & 2028
5.1.2 Clinic
5.1.3 Hospital
5.1.4 Others
5.2 By Application - Global Metastatic Ovarian Cancer Drug Revenue & Forecasts
5.2.1 By Application - Global Metastatic Ovarian Cancer Drug Revenue, 2017-2022
5.2.2 By Application - Global Metastatic Ovarian Cancer Drug Revenue, 2023-2028
5.2.3 By Application - Global Metastatic Ovarian Cancer Drug Revenue Market Share, 2017-2028
5.3 By Application - Global Metastatic Ovarian Cancer Drug Sales & Forecasts
5.3.1 By Application - Global Metastatic Ovarian Cancer Drug Sales, 2017-2022
5.3.2 By Application - Global Metastatic Ovarian Cancer Drug Sales, 2023-2028
5.3.3 By Application - Global Metastatic Ovarian Cancer Drug Sales Market Share, 2017-2028
5.4 By Application - Global Metastatic Ovarian Cancer Drug Price (Manufacturers Selling Prices), 2017-2028
6 Sights by Region
6.1 By Region - Global Metastatic Ovarian Cancer Drug Market Size, 2021 & 2028
6.2 By Region - Global Metastatic Ovarian Cancer Drug Revenue & Forecasts
6.2.1 By Region - Global Metastatic Ovarian Cancer Drug Revenue, 2017-2022
6.2.2 By Region - Global Metastatic Ovarian Cancer Drug Revenue, 2023-2028
6.2.3 By Region - Global Metastatic Ovarian Cancer Drug Revenue Market Share, 2017-2028
6.3 By Region - Global Metastatic Ovarian Cancer Drug Sales & Forecasts
6.3.1 By Region - Global Metastatic Ovarian Cancer Drug Sales, 2017-2022
6.3.2 By Region - Global Metastatic Ovarian Cancer Drug Sales, 2023-2028
6.3.3 By Region - Global Metastatic Ovarian Cancer Drug Sales Market Share, 2017-2028
6.4 North America
6.4.1 By Country - North America Metastatic Ovarian Cancer Drug Revenue, 2017-2028
6.4.2 By Country - North America Metastatic Ovarian Cancer Drug Sales, 2017-2028
6.4.3 US Metastatic Ovarian Cancer Drug Market Size, 2017-2028
6.4.4 Canada Metastatic Ovarian Cancer Drug Market Size, 2017-2028
6.4.5 Mexico Metastatic Ovarian Cancer Drug Market Size, 2017-2028
6.5 Europe
6.5.1 By Country - Europe Metastatic Ovarian Cancer Drug Revenue, 2017-2028
6.5.2 By Country - Europe Metastatic Ovarian Cancer Drug Sales, 2017-2028
6.5.3 Germany Metastatic Ovarian Cancer Drug Market Size, 2017-2028
6.5.4 France Metastatic Ovarian Cancer Drug Market Size, 2017-2028
6.5.5 U.K. Metastatic Ovarian Cancer Drug Market Size, 2017-2028
6.5.6 Italy Metastatic Ovarian Cancer Drug Market Size, 2017-2028
6.5.7 Russia Metastatic Ovarian Cancer Drug Market Size, 2017-2028
6.5.8 Nordic Countries Metastatic Ovarian Cancer Drug Market Size, 2017-2028
6.5.9 Benelux Metastatic Ovarian Cancer Drug Market Size, 2017-2028
6.6 Asia
6.6.1 By Region - Asia Metastatic Ovarian Cancer Drug Revenue, 2017-2028
6.6.2 By Region - Asia Metastatic Ovarian Cancer Drug Sales, 2017-2028
6.6.3 China Metastatic Ovarian Cancer Drug Market Size, 2017-2028
6.6.4 Japan Metastatic Ovarian Cancer Drug Market Size, 2017-2028
6.6.5 South Korea Metastatic Ovarian Cancer Drug Market Size, 2017-2028
6.6.6 Southeast Asia Metastatic Ovarian Cancer Drug Market Size, 2017-2028
6.6.7 India Metastatic Ovarian Cancer Drug Market Size, 2017-2028
6.7 South America
6.7.1 By Country - South America Metastatic Ovarian Cancer Drug Revenue, 2017-2028
6.7.2 By Country - South America Metastatic Ovarian Cancer Drug Sales, 2017-2028
6.7.3 Brazil Metastatic Ovarian Cancer Drug Market Size, 2017-2028
6.7.4 Argentina Metastatic Ovarian Cancer Drug Market Size, 2017-2028
6.8 Middle East & Africa
6.8.1 By Country - Middle East & Africa Metastatic Ovarian Cancer Drug Revenue, 2017-2028
6.8.2 By Country - Middle East & Africa Metastatic Ovarian Cancer Drug Sales, 2017-2028
6.8.3 Turkey Metastatic Ovarian Cancer Drug Market Size, 2017-2028
6.8.4 Israel Metastatic Ovarian Cancer Drug Market Size, 2017-2028
6.8.5 Saudi Arabia Metastatic Ovarian Cancer Drug Market Size, 2017-2028
6.8.6 UAE Metastatic Ovarian Cancer Drug Market Size, 2017-2028
7 Manufacturers & Brands Profiles
7.1 Adgero Biopharmaceuticals Inc
7.1.1 Adgero Biopharmaceuticals Inc Corporate Summary
7.1.2 Adgero Biopharmaceuticals Inc Business Overview
7.1.3 Adgero Biopharmaceuticals Inc Metastatic Ovarian Cancer Drug Major Product Offerings
7.1.4 Adgero Biopharmaceuticals Inc Metastatic Ovarian Cancer Drug Sales and Revenue in Global (2017-2022)
7.1.5 Adgero Biopharmaceuticals Inc Key News
7.2 Cellceutix Corporation
7.2.1 Cellceutix Corporation Corporate Summary
7.2.2 Cellceutix Corporation Business Overview
7.2.3 Cellceutix Corporation Metastatic Ovarian Cancer Drug Major Product Offerings
7.2.4 Cellceutix Corporation Metastatic Ovarian Cancer Drug Sales and Revenue in Global (2017-2022)
7.2.5 Cellceutix Corporation Key News
7.3 Eisai Co., Ltd.
7.3.1 Eisai Co., Ltd. Corporate Summary
7.3.2 Eisai Co., Ltd. Business Overview
7.3.3 Eisai Co., Ltd. Metastatic Ovarian Cancer Drug Major Product Offerings
7.3.4 Eisai Co., Ltd. Metastatic Ovarian Cancer Drug Sales and Revenue in Global (2017-2022)
7.3.5 Eisai Co., Ltd. Key News
7.4 F. Hoffmann-La Roche Ltd.
7.4.1 F. Hoffmann-La Roche Ltd. Corporate Summary
7.4.2 F. Hoffmann-La Roche Ltd. Business Overview
7.4.3 F. Hoffmann-La Roche Ltd. Metastatic Ovarian Cancer Drug Major Product Offerings
7.4.4 F. Hoffmann-La Roche Ltd. Metastatic Ovarian Cancer Drug Sales and Revenue in Global (2017-2022)
7.4.5 F. Hoffmann-La Roche Ltd. Key News
7.5 Immune Design Corp.
7.5.1 Immune Design Corp. Corporate Summary
7.5.2 Immune Design Corp. Business Overview
7.5.3 Immune Design Corp. Metastatic Ovarian Cancer Drug Major Product Offerings
7.5.4 Immune Design Corp. Metastatic Ovarian Cancer Drug Sales and Revenue in Global (2017-2022)
7.5.5 Immune Design Corp. Key News
7.6 Millennium Pharmaceuticals Inc
7.6.1 Millennium Pharmaceuticals Inc Corporate Summary
7.6.2 Millennium Pharmaceuticals Inc Business Overview
7.6.3 Millennium Pharmaceuticals Inc Metastatic Ovarian Cancer Drug Major Product Offerings
7.6.4 Millennium Pharmaceuticals Inc Metastatic Ovarian Cancer Drug Sales and Revenue in Global (2017-2022)
7.6.5 Millennium Pharmaceuticals Inc Key News
7.7 MolMed S.p.A.
7.7.1 MolMed S.p.A. Corporate Summary
7.7.2 MolMed S.p.A. Business Overview
7.7.3 MolMed S.p.A. Metastatic Ovarian Cancer Drug Major Product Offerings
7.7.4 MolMed S.p.A. Metastatic Ovarian Cancer Drug Sales and Revenue in Global (2017-2022)
7.7.5 MolMed S.p.A. Key News
7.8 Natco Pharma Limited
7.8.1 Natco Pharma Limited Corporate Summary
7.8.2 Natco Pharma Limited Business Overview
7.8.3 Natco Pharma Limited Metastatic Ovarian Cancer Drug Major Product Offerings
7.8.4 Natco Pharma Limited Metastatic Ovarian Cancer Drug Sales and Revenue in Global (2017-2022)
7.8.5 Natco Pharma Limited Key News
7.9 Northwest Biotherapeutics, Inc.
7.9.1 Northwest Biotherapeutics, Inc. Corporate Summary
7.9.2 Northwest Biotherapeutics, Inc. Business Overview
7.9.3 Northwest Biotherapeutics, Inc. Metastatic Ovarian Cancer Drug Major Product Offerings
7.9.4 Northwest Biotherapeutics, Inc. Metastatic Ovarian Cancer Drug Sales and Revenue in Global (2017-2022)
7.9.5 Northwest Biotherapeutics, Inc. Key News
7.10 Pfizer Inc.
7.10.1 Pfizer Inc. Corporate Summary
7.10.2 Pfizer Inc. Business Overview
7.10.3 Pfizer Inc. Metastatic Ovarian Cancer Drug Major Product Offerings
7.10.4 Pfizer Inc. Metastatic Ovarian Cancer Drug Sales and Revenue in Global (2017-2022)
7.10.5 Pfizer Inc. Key News
7.11 Richter Gedeon Nyrt.
7.11.1 Richter Gedeon Nyrt. Corporate Summary
7.11.2 Richter Gedeon Nyrt. Metastatic Ovarian Cancer Drug Business Overview
7.11.3 Richter Gedeon Nyrt. Metastatic Ovarian Cancer Drug Major Product Offerings
7.11.4 Richter Gedeon Nyrt. Metastatic Ovarian Cancer Drug Sales and Revenue in Global (2017-2022)
7.11.5 Richter Gedeon Nyrt. Key News
7.12 Sumitomo Dainippon Pharma Co., Ltd.
7.12.1 Sumitomo Dainippon Pharma Co., Ltd. Corporate Summary
7.12.2 Sumitomo Dainippon Pharma Co., Ltd. Metastatic Ovarian Cancer Drug Business Overview
7.12.3 Sumitomo Dainippon Pharma Co., Ltd. Metastatic Ovarian Cancer Drug Major Product Offerings
7.12.4 Sumitomo Dainippon Pharma Co., Ltd. Metastatic Ovarian Cancer Drug Sales and Revenue in Global (2017-2022)
7.12.5 Sumitomo Dainippon Pharma Co., Ltd. Key News
7.13 VG Life Sciences, Inc.
7.13.1 VG Life Sciences, Inc. Corporate Summary
7.13.2 VG Life Sciences, Inc. Metastatic Ovarian Cancer Drug Business Overview
7.13.3 VG Life Sciences, Inc. Metastatic Ovarian Cancer Drug Major Product Offerings
7.13.4 VG Life Sciences, Inc. Metastatic Ovarian Cancer Drug Sales and Revenue in Global (2017-2022)
7.13.5 VG Life Sciences, Inc. Key News
8 Global Metastatic Ovarian Cancer Drug Production Capacity, Analysis
8.1 Global Metastatic Ovarian Cancer Drug Production Capacity, 2017-2028
8.2 Metastatic Ovarian Cancer Drug Production Capacity of Key Manufacturers in Global Market
8.3 Global Metastatic Ovarian Cancer Drug Production by Region
9 Key Market Trends, Opportunity, Drivers and Restraints
9.1 Market Opportunities & Trends
9.2 Market Drivers
9.3 Market Restraints
10 Metastatic Ovarian Cancer Drug Supply Chain Analysis
10.1 Metastatic Ovarian Cancer Drug Industry Value Chain
10.2 Metastatic Ovarian Cancer Drug Upstream Market
10.3 Metastatic Ovarian Cancer Drug Downstream and Clients
10.4 Marketing Channels Analysis
10.4.1 Marketing Channels
10.4.2 Metastatic Ovarian Cancer Drug Distributors and Sales Agents in Global
11 Conclusion
12 Appendix
12.1 Note
12.2 Examples of Clients
12.3 Disclaimer
LIST OF TABLES & FIGURES
List of Tables
Table 1. Key Players of Metastatic Ovarian Cancer Drug in Global Market
Table 2. Top Metastatic Ovarian Cancer Drug Players in Global Market, Ranking by Revenue (2021)
Table 3. Global Metastatic Ovarian Cancer Drug Revenue by Companies, (US$, Mn), 2017-2022
Table 4. Global Metastatic Ovarian Cancer Drug Revenue Share by Companies, 2017-2022
Table 5. Global Metastatic Ovarian Cancer Drug Sales by Companies, (K Pcs), 2017-2022
Table 6. Global Metastatic Ovarian Cancer Drug Sales Share by Companies, 2017-2022
Table 7. Key Manufacturers Metastatic Ovarian Cancer Drug Price (2017-2022) & (USD/Pcs)
Table 8. Global Manufacturers Metastatic Ovarian Cancer Drug Product Type
Table 9. List of Global Tier 1 Metastatic Ovarian Cancer Drug Companies, Revenue (US$, Mn) in 2021 and Market Share
Table 10. List of Global Tier 2 and Tier 3 Metastatic Ovarian Cancer Drug Companies, Revenue (US$, Mn) in 2021 and Market Share
Table 11. By Type ? Global Metastatic Ovarian Cancer Drug Revenue, (US$, Mn), 2021 & 2028
Table 12. By Type - Global Metastatic Ovarian Cancer Drug Revenue (US$, Mn), 2017-2022
Table 13. By Type - Global Metastatic Ovarian Cancer Drug Revenue (US$, Mn), 2023-2028
Table 14. By Type - Global Metastatic Ovarian Cancer Drug Sales (K Pcs), 2017-2022
Table 15. By Type - Global Metastatic Ovarian Cancer Drug Sales (K Pcs), 2023-2028
Table 16. By Application ? Global Metastatic Ovarian Cancer Drug Revenue, (US$, Mn), 2021 & 2028
Table 17. By Application - Global Metastatic Ovarian Cancer Drug Revenue (US$, Mn), 2017-2022
Table 18. By Application - Global Metastatic Ovarian Cancer Drug Revenue (US$, Mn), 2023-2028
Table 19. By Application - Global Metastatic Ovarian Cancer Drug Sales (K Pcs), 2017-2022
Table 20. By Application - Global Metastatic Ovarian Cancer Drug Sales (K Pcs), 2023-2028
Table 21. By Region ? Global Metastatic Ovarian Cancer Drug Revenue, (US$, Mn), 2021 VS 2028
Table 22. By Region - Global Metastatic Ovarian Cancer Drug Revenue (US$, Mn), 2017-2022
Table 23. By Region - Global Metastatic Ovarian Cancer Drug Revenue (US$, Mn), 2023-2028
Table 24. By Region - Global Metastatic Ovarian Cancer Drug Sales (K Pcs), 2017-2022
Table 25. By Region - Global Metastatic Ovarian Cancer Drug Sales (K Pcs), 2023-2028
Table 26. By Country - North America Metastatic Ovarian Cancer Drug Revenue, (US$, Mn), 2017-2022
Table 27. By Country - North America Metastatic Ovarian Cancer Drug Revenue, (US$, Mn), 2023-2028
Table 28. By Country - North America Metastatic Ovarian Cancer Drug Sales, (K Pcs), 2017-2022
Table 29. By Country - North America Metastatic Ovarian Cancer Drug Sales, (K Pcs), 2023-2028
Table 30. By Country - Europe Metastatic Ovarian Cancer Drug Revenue, (US$, Mn), 2017-2022
Table 31. By Country - Europe Metastatic Ovarian Cancer Drug Revenue, (US$, Mn), 2023-2028
Table 32. By Country - Europe Metastatic Ovarian Cancer Drug Sales, (K Pcs), 2017-2022
Table 33. By Country - Europe Metastatic Ovarian Cancer Drug Sales, (K Pcs), 2023-2028
Table 34. By Region - Asia Metastatic Ovarian Cancer Drug Revenue, (US$, Mn), 2017-2022
Table 35. By Region - Asia Metastatic Ovarian Cancer Drug Revenue, (US$, Mn), 2023-2028
Table 36. By Region - Asia Metastatic Ovarian Cancer Drug Sales, (K Pcs), 2017-2022
Table 37. By Region - Asia Metastatic Ovarian Cancer Drug Sales, (K Pcs), 2023-2028
Table 38. By Country - South America Metastatic Ovarian Cancer Drug Revenue, (US$, Mn), 2017-2022
Table 39. By Country - South America Metastatic Ovarian Cancer Drug Revenue, (US$, Mn), 2023-2028
Table 40. By Country - South America Metastatic Ovarian Cancer Drug Sales, (K Pcs), 2017-2022
Table 41. By Country - South America Metastatic Ovarian Cancer Drug Sales, (K Pcs), 2023-2028
Table 42. By Country - Middle East & Africa Metastatic Ovarian Cancer Drug Revenue, (US$, Mn), 2017-2022
Table 43. By Country - Middle East & Africa Metastatic Ovarian Cancer Drug Revenue, (US$, Mn), 2023-2028
Table 44. By Country - Middle East & Africa Metastatic Ovarian Cancer Drug Sales, (K Pcs), 2017-2022
Table 45. By Country - Middle East & Africa Metastatic Ovarian Cancer Drug Sales, (K Pcs), 2023-2028
Table 46. Adgero Biopharmaceuticals Inc Corporate Summary
Table 47. Adgero Biopharmaceuticals Inc Metastatic Ovarian Cancer Drug Product Offerings
Table 48. Adgero Biopharmaceuticals Inc Metastatic Ovarian Cancer Drug Sales (K Pcs), Revenue (US$, Mn) and Average Price (USD/Pcs) (2017-2022)
Table 49. Cellceutix Corporation Corporate Summary
Table 50. Cellceutix Corporation Metastatic Ovarian Cancer Drug Product Offerings
Table 51. Cellceutix Corporation Metastatic Ovarian Cancer Drug Sales (K Pcs), Revenue (US$, Mn) and Average Price (USD/Pcs) (2017-2022)
Table 52. Eisai Co., Ltd. Corporate Summary
Table 53. Eisai Co., Ltd. Metastatic Ovarian Cancer Drug Product Offerings
Table 54. Eisai Co., Ltd. Metastatic Ovarian Cancer Drug Sales (K Pcs), Revenue (US$, Mn) and Average Price (USD/Pcs) (2017-2022)
Table 55. F. Hoffmann-La Roche Ltd. Corporate Summary
Table 56. F. Hoffmann-La Roche Ltd. Metastatic Ovarian Cancer Drug Product Offerings
Table 57. F. Hoffmann-La Roche Ltd. Metastatic Ovarian Cancer Drug Sales (K Pcs), Revenue (US$, Mn) and Average Price (USD/Pcs) (2017-2022)
Table 58. Immune Design Corp. Corporate Summary
Table 59. Immune Design Corp. Metastatic Ovarian Cancer Drug Product Offerings
Table 60. Immune Design Corp. Metastatic Ovarian Cancer Drug Sales (K Pcs), Revenue (US$, Mn) and Average Price (USD/Pcs) (2017-2022)
Table 61. Millennium Pharmaceuticals Inc Corporate Summary
Table 62. Millennium Pharmaceuticals Inc Metastatic Ovarian Cancer Drug Product Offerings
Table 63. Millennium Pharmaceuticals Inc Metastatic Ovarian Cancer Drug Sales (K Pcs), Revenue (US$, Mn) and Average Price (USD/Pcs) (2017-2022)
Table 64. MolMed S.p.A. Corporate Summary
Table 65. MolMed S.p.A. Metastatic Ovarian Cancer Drug Product Offerings
Table 66. MolMed S.p.A. Metastatic Ovarian Cancer Drug Sales (K Pcs), Revenue (US$, Mn) and Average Price (USD/Pcs) (2017-2022)
Table 67. Natco Pharma Limited Corporate Summary
Table 68. Natco Pharma Limited Metastatic Ovarian Cancer Drug Product Offerings
Table 69. Natco Pharma Limited Metastatic Ovarian Cancer Drug Sales (K Pcs), Revenue (US$, Mn) and Average Price (USD/Pcs) (2017-2022)
Table 70. Northwest Biotherapeutics, Inc. Corporate Summary
Table 71. Northwest Biotherapeutics, Inc. Metastatic Ovarian Cancer Drug Product Offerings
Table 72. Northwest Biotherapeutics, Inc. Metastatic Ovarian Cancer Drug Sales (K Pcs), Revenue (US$, Mn) and Average Price (USD/Pcs) (2017-2022)
Table 73. Pfizer Inc. Corporate Summary
Table 74. Pfizer Inc. Metastatic Ovarian Cancer Drug Product Offerings
Table 75. Pfizer Inc. Metastatic Ovarian Cancer Drug Sales (K Pcs), Revenue (US$, Mn) and Average Price (USD/Pcs) (2017-2022)
Table 76. Richter Gedeon Nyrt. Corporate Summary
Table 77. Richter Gedeon Nyrt. Metastatic Ovarian Cancer Drug Product Offerings
Table 78. Richter Gedeon Nyrt. Metastatic Ovarian Cancer Drug Sales (K Pcs), Revenue (US$, Mn) and Average Price (USD/Pcs) (2017-2022)
Table 79. Sumitomo Dainippon Pharma Co., Ltd. Corporate Summary
Table 80. Sumitomo Dainippon Pharma Co., Ltd. Metastatic Ovarian Cancer Drug Product Offerings
Table 81. Sumitomo Dainippon Pharma Co., Ltd. Metastatic Ovarian Cancer Drug Sales (K Pcs), Revenue (US$, Mn) and Average Price (USD/Pcs) (2017-2022)
Table 82. VG Life Sciences, Inc. Corporate Summary
Table 83. VG Life Sciences, Inc. Metastatic Ovarian Cancer Drug Product Offerings
Table 84. VG Life Sciences, Inc. Metastatic Ovarian Cancer Drug Sales (K Pcs), Revenue (US$, Mn) and Average Price (USD/Pcs) (2017-2022)
Table 85. Metastatic Ovarian Cancer Drug Production Capacity (K Pcs) of Key Manufacturers in Global Market, 2020-2022 (K Pcs)
Table 86. Global Metastatic Ovarian Cancer Drug Capacity Market Share of Key Manufacturers, 2020-2022
Table 87. Global Metastatic Ovarian Cancer Drug Production by Region, 2017-2022 (K Pcs)
Table 88. Global Metastatic Ovarian Cancer Drug Production by Region, 2023-2028 (K Pcs)
Table 89. Metastatic Ovarian Cancer Drug Market Opportunities & Trends in Global Market
Table 90. Metastatic Ovarian Cancer Drug Market Drivers in Global Market
Table 91. Metastatic Ovarian Cancer Drug Market Restraints in Global Market
Table 92. Metastatic Ovarian Cancer Drug Raw Materials
Table 93. Metastatic Ovarian Cancer Drug Raw Materials Suppliers in Global Market
Table 94. Typical Metastatic Ovarian Cancer Drug Downstream
Table 95. Metastatic Ovarian Cancer Drug Downstream Clients in Global Market
Table 96. Metastatic Ovarian Cancer Drug Distributors and Sales Agents in Global Market
List of Figures
Figure 1. Metastatic Ovarian Cancer Drug Segment by Type
Figure 2. Metastatic Ovarian Cancer Drug Segment by Application
Figure 3. Global Metastatic Ovarian Cancer Drug Market Overview: 2021
Figure 4. Key Caveats
Figure 5. Global Metastatic Ovarian Cancer Drug Market Size: 2021 VS 2028 (US$, Mn)
Figure 6. Global Metastatic Ovarian Cancer Drug Revenue, 2017-2028 (US$, Mn)
Figure 7. Metastatic Ovarian Cancer Drug Sales in Global Market: 2017-2028 (K Pcs)
Figure 8. The Top 3 and 5 Players Market Share by Metastatic Ovarian Cancer Drug Revenue in 2021
Figure 9. By Type - Global Metastatic Ovarian Cancer Drug Sales Market Share, 2017-2028
Figure 10. By Type - Global Metastatic Ovarian Cancer Drug Revenue Market Share, 2017-2028
Figure 11. By Type - Global Metastatic Ovarian Cancer Drug Price (USD/Pcs), 2017-2028
Figure 12. By Application - Global Metastatic Ovarian Cancer Drug Sales Market Share, 2017-2028
Figure 13. By Application - Global Metastatic Ovarian Cancer Drug Revenue Market Share, 2017-2028
Figure 14. By Application - Global Metastatic Ovarian Cancer Drug Price (USD/Pcs), 2017-2028
Figure 15. By Region - Global Metastatic Ovarian Cancer Drug Sales Market Share, 2017-2028
Figure 16. By Region - Global Metastatic Ovarian Cancer Drug Revenue Market Share, 2017-2028
Figure 17. By Country - North America Metastatic Ovarian Cancer Drug Revenue Market Share, 2017-2028
Figure 18. By Country - North America Metastatic Ovarian Cancer Drug Sales Market Share, 2017-2028
Figure 19. US Metastatic Ovarian Cancer Drug Revenue, (US$, Mn), 2017-2028
Figure 20. Canada Metastatic Ovarian Cancer Drug Revenue, (US$, Mn), 2017-2028
Figure 21. Mexico Metastatic Ovarian Cancer Drug Revenue, (US$, Mn), 2017-2028
Figure 22. By Country - Europe Metastatic Ovarian Cancer Drug Revenue Market Share, 2017-2028
Figure 23. By Country - Europe Metastatic Ovarian Cancer Drug Sales Market Share, 2017-2028
Figure 24. Germany Metastatic Ovarian Cancer Drug Revenue, (US$, Mn), 2017-2028
Figure 25. France Metastatic Ovarian Cancer Drug Revenue, (US$, Mn), 2017-2028
Figure 26. U.K. Metastatic Ovarian Cancer Drug Revenue, (US$, Mn), 2017-2028
Figure 27. Italy Metastatic Ovarian Cancer Drug Revenue, (US$, Mn), 2017-2028
Figure 28. Russia Metastatic Ovarian Cancer Drug Revenue, (US$, Mn), 2017-2028
Figure 29. Nordic Countries Metastatic Ovarian Cancer Drug Revenue, (US$, Mn), 2017-2028
Figure 30. Benelux Metastatic Ovarian Cancer Drug Revenue, (US$, Mn), 2017-2028
Figure 31. By Region - Asia Metastatic Ovarian Cancer Drug Revenue Market Share, 2017-2028
Figure 32. By Region - Asia Metastatic Ovarian Cancer Drug Sales Market Share, 2017-2028
Figure 33. China Metastatic Ovarian Cancer Drug Revenue, (US$, Mn), 2017-2028
Figure 34. Japan Metastatic Ovarian Cancer Drug Revenue, (US$, Mn), 2017-2028
Figure 35. South Korea Metastatic Ovarian Cancer Drug Revenue, (US$, Mn), 2017-2028
Figure 36. Southeast Asia Metastatic Ovarian Cancer Drug Revenue, (US$, Mn), 2017-2028
Figure 37. India Metastatic Ovarian Cancer Drug Revenue, (US$, Mn), 2017-2028
Figure 38. By Country - South America Metastatic Ovarian Cancer Drug Revenue Market Share, 2017-2028
Figure 39. By Country - South America Metastatic Ovarian Cancer Drug Sales Market Share, 2017-2028
Figure 40. Brazil Metastatic Ovarian Cancer Drug Revenue, (US$, Mn), 2017-2028
Figure 41. Argentina Metastatic Ovarian Cancer Drug Revenue, (US$, Mn), 2017-2028
Figure 42. By Country - Middle East & Africa Metastatic Ovarian Cancer Drug Revenue Market Share, 2017-2028
Figure 43. By Country - Middle East & Africa Metastatic Ovarian Cancer Drug Sales Market Share, 2017-2028
Figure 44. Turkey Metastatic Ovarian Cancer Drug Revenue, (US$, Mn), 2017-2028
Figure 45. Israel Metastatic Ovarian Cancer Drug Revenue, (US$, Mn), 2017-2028
Figure 46. Saudi Arabia Metastatic Ovarian Cancer Drug Revenue, (US$, Mn), 2017-2028
Figure 47. UAE Metastatic Ovarian Cancer Drug Revenue, (US$, Mn), 2017-2028
Figure 48. Global Metastatic Ovarian Cancer Drug Production Capacity (K Pcs), 2017-2028
Figure 49. The Percentage of Production Metastatic Ovarian Cancer Drug by Region, 2021 VS 2028
Figure 50. Metastatic Ovarian Cancer Drug Industry Value Chain
Figure 51. Marketing Channels
